Second malignancies after radiotherapy for prostate cancer: Systematic review and meta-analysis

BMJ (Online)

Volumn 352, Issue , 2016, Pages

  Wallis, Christopher J D ^a,b   Mahar, Alyson L ^a   Choo, Richard ^c   Herschorn, Sender ^a   Kodama, Ronald T ^a   Shah, Prakesh S ^a,b   Danjoux, Cyril ^d   Narod, Steven A ^a   Nam, Robert K ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c MAYO CLINIC   (United States)

^d Canada   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BLADDER CANCER; BRACHYTHERAPY; CANCER RADIOTHERAPY; CANCER RISK; COLORECTAL CANCER; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; HAZARD RATIO; HEMATOLOGIC MALIGNANCY; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LUNG CANCER; MANTEL HAENSZEL TEST; META ANALYSIS; ODDS RATIO; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION EXPOSURE; RECTUM CANCER; REVIEW; RISK ASSESSMENT; SECOND CANCER; SYSTEMATIC REVIEW; TIME TO TREATMENT; ADVERSE EFFECTS; COLORECTAL NEOPLASMS; INCIDENCE; MALE; NEOPLASMS, SECOND PRIMARY; PROSTATIC NEOPLASMS; RECTAL NEOPLASMS; URINARY BLADDER NEOPLASMS;

BRACHYTHERAPY; COLORECTAL NEOPLASMS; HUMANS; INCIDENCE; MALE; NEOPLASMS, SECOND PRIMARY; PROSTATIC NEOPLASMS; RECTAL NEOPLASMS; RISK ASSESSMENT; URINARY BLADDER NEOPLASMS;

EID: 84960367641     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.i851     Document Type: Review

References (51)

1. Heidenreich A, Bastian PJ, Bellmunt J, et al. European Association of Urology. EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol 2014;65:124-37. doi:10.1016/j.eururo.2013.09.046.
2. Potosky AL, Davis WW, Hoffman RM, et al. Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. J Natl Cancer Inst 2004;96:1358-67. doi:10.1093/jnci/djh259.
3. Resnick MJ, Koyama T, Fan KH, et al. Long-term functional outcomes after treatment for localized prostate cancer. N Engl J Med 2013;368:436-45. doi:10.1056/NEJMoa1209978.
4. Wallis CJ, Cheung P, Herschorn S, et al. Complications following surgery with or without radiotherapy or radiotherapy alone for prostate cancer. Br J Cancer 2015;112:977-82. doi:10.1038/bjc.2015.54.
5. Wallis CJ, Herschorn S, Saskin R, et al. Complications after radical prostatectomy or radiotherapy for prostate cancer: results of a population-based, propensity score-matched analysis. Urology 2015;85:621-7. doi:10.1016/j.urology.2014.11.037.
6. Nam RK, Cheung P, Herschorn S, et al. Incidence of complications other than urinary incontinence or erectile dysfunction after radical prostatectomy or radiotherapy for prostate cancer: a populationbased cohort study. Lancet Oncol 2014;15:223-31. doi:10.1016/S1470-2045 (13) 70606-5.
7. Berrington de Gonzalez A, Curtis RE, Kry SF, et al. Proportion of second cancers attributable to radiotherapy treatment in adults: a cohort study in the US SEER cancer registries. Lancet Oncol 2011;12:353-60. doi:10.1016/S1470-2045 (11) 70061-4.
8. Brenner DJ, Curtis RE, Hall EJ, Ron E. Second malignancies in prostate carcinoma patients after radiotherapy compared with surgery. Cancer 2000;88:398-406. doi:10.1002/(SICI)1097-0142 (20000115) 88:2<398::AID-CNCR22>3.0. CO;2-V.
9. Kendal WS, Eapen L, Macrae R, Malone S, Nicholas G. Prostatic irradiation is not associated with any measurable increase in the risk of subsequent rectal cancer [Erratum appears in Int J Radiat Oncol Biol Phys. 2008 Mar. 15;70(4):1294-5]. Int J Radiat Oncol Biol Phys 2006;65:661-8. doi:10.1016/j.ijrobp. 2005.11.013.
10. Zelefsky MJ, Pei X, Teslova T, et al. Secondary cancers after intensity-modulated radiotherapy, brachytherapy and radical prostatectomy for the treatment of prostate cancer: incidence and cause-specific survival outcomes according to the initial treatment intervention. BJU Int 2012;110:1696-701. doi:10.1111/j.1464-410X.2012.11385.x.
11. Müller AC, Ganswindt U, Bamberg M, Belka C. Risk of second malignancies after prostate irradiation? Strahlenther Onkol 2007;183:605-9. doi:10.1007/s00066-007-1786-y.
12. Bostrom PJ, Soloway MS. Secondary cancer after radiotherapy for prostate cancer: should we be more aware of the risk? Eur Urol 2007;52:973-82. doi:10.1016/j.eururo.2007.07.002.
13. Murray L, Henry A, Hoskin P, Siebert FA, Venselaar J. PROBATE group of GEC ESTRO. Second primary cancers after radiation for prostate cancer: a systematic review of the clinical data and impact of treatment technique. Radiother Oncol 2014;110:213-28. doi:10.1016/j.radonc.2013.12.012.
14. Goldstraw MA, Payne H, Kirby RS. What are the risks of second cancer formation after radiotherapy to the prostate? BJU Int 2006;98:489-91. doi:10.1111/j.1464-410X.2006.06288.x.
15. Jin T, Song T, Deng S, Wang K. Radiation-induced secondary malignancy in prostate cancer: a systematic review and metaanalysis. Urol Int 2014;93:279-88. doi:10.1159/000356115.
16. Frieben H. Demonstration eines Cancroid des rechten Handrueckens, das sich nach langdauernder Einwirkung von Roentgenstrahlen entwickelt hatte. Fortschr Geb Rontgenstr 1902;6:106-11.
17. Lehnert BE, Goodwin EH, Deshpande A. Extracellular factor (s) following exposure to alpha particles can cause sister chromatid exchanges in normal human cells. Cancer Res 1997;57:2164-71.9187116.
18. Narayanan PK, Goodwin EH, Lehnert BE. Alpha particles initiate biological production of superoxide anions and hydrogen peroxide in human cells. Cancer Res 1997;57:3963-71.
19. Narayanan PK, LaRue KE, Goodwin EH, Lehnert BE. Alpha particles induce the production of interleukin-8 by human cells. Radiat Res 1999;152:57-63. doi:10.2307/3580049.
20. Azzam EI, de Toledo SM, Gooding T, Little JB. Intercellular communication is involved in the bystander regulation of gene expression in human cells exposed to very low fluences of alpha particles. Radiat Res 1998;150:497-504. doi:10.2307/3579865.
21. Murray EM, Werner D, Greeff EA, Taylor DA. Postradiation sarcomas: 20 cases and a literature review. Int J Radiat Oncol Biol Phys 1999;45:951-61. doi:10.1016/S0360-3016 (99) 00279-5.
22. Cahan WG, Woodard HQ, Higinbotham NL, Stewart FW, Coley BL. Sarcoma arising in irradiated bone; report of 11 cases. Cancer 1948;1:3-29. doi:10.1002/1097-0142 (194805) 1:1<3:AID-CNCR2820010103>3.0. CO;2-7.
23. Sale KA, Wallace DI, Girod DA, Tsue TT. Radiation-induced malignancy of the head and neck. Otolaryngol Head Neck Surg 2004;131:643-5. doi:10.1016/j.otohns.2004.05.012.
24. Moher D, Liberati A, Tetzlaff J, Altman DG. PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 2009;62:1006-12. doi:10.1016/j. jclinepi.2009.06.005.
25. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000;283:2008-12. doi:10.1001/jama.283.15.2008.
26. Deeks JJ, Dinnes J, D'Amico R, et al. International Stroke Trial Collaborative Group European Carotid Surgery Trial Collaborative Group. Evaluating non-randomised intervention studies. Health Technol Assess 2003;7:iii-x, 1-173. doi:10.3310/hta7270.
27. Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. Secondary The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. 2011. http://www.ohri.ca/programs/clinical-epidemiology/oxford.asp.
28. Robins J, Breslow N, Greenland S. Estimators of the Mantel-Haenszel variance consistent in both sparse data and large-strata limiting models. Biometrics 1986;42:311-23. doi:10.2307/2531052.
29. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60. doi:10.1136/bmj.327.7414.557.
30. Pickles T, Phillips N. The risk of second malignancy in men with prostate cancer treated with or without radiation in British Columbia, 1984-2000. Radiother Oncol 2002;65:145-51. doi:10.1016/S0167-8140 (02) 00307-9.
31. Margel D, Baniel J, Wasserberg N, Bar-Chana M, Yossepowitch O. Radiation therapy for prostate cancer increases the risk of subsequent rectal cancer. Ann Surg 2011;254:947-50. doi:10.1097/SLA.0b013e3182382fd5.
32. Huang J, Kestin LL, Ye H, Wallace M, Martinez AA, Vicini FA. Analysis of second malignancies after modern radiotherapy versus prostatectomy for localized prostate cancer. Radiother Oncol 2011;98:81-6. doi:10.1016/j.radonc.2010.09.012.
33. Singh A, Kinoshita Y, Rovito PM Jr, et al. Higher than expected association of clinical prostate and bladder cancers. J Urol 2008;179(Suppl):S2-5. doi:10.1016/j.juro.2008.03.130.
34. Abdel-Wahab M, Reis IM, Hamilton K. Second primary cancer after radiotherapy for prostate cancer - a seer analysis of brachytherapy versus external beam radiotherapy. Int J Radiat Oncol Biol Phys 2008;72:58-68. doi:10.1016/j.ijrobp. 2007.12.043.
35. Abern MR, Dude AM, Tsivian M, Coogan CL. The characteristics of bladder cancer after radiotherapy for prostate cancer. Urol Oncol 2013;31:1628-34. doi:10.1016/j.urolonc.2012.04.006.
36. Baxter NN, Tepper JE, Durham SB, Rothenberger DA, Virnig BA. Increased risk of rectal cancer after prostate radiation: a populationbased study. Gastroenterology 2005;128:819-24. doi: 10.1053/j. gastro.2004.12.038.
37. Bhojani N, Capitanio U, Suardi N, et al. The rate of secondary malignancies after radical prostatectomy versus external beam radiation therapy for localized prostate cancer: a population-based study on 17, 845 patients. Int J Radiat Oncol Biol Phys 2010;76:342-8. doi:10.1016/j.ijrobp. 2009.02.011.
38. Boorjian S, Cowan JE, Konety BR, et al. Cancer of the Prostate Strategic Urologic Research Endeavor Investigators. Bladder cancer incidence and risk factors in men with prostate cancer: results from Cancer of the Prostate Strategic Urologic Research Endeavor. J Urol 2007;177:883-7, discussion 887-8. doi:10.1016/j.juro.2006.10.071.
39. Davis EJ, Beebe-Dimmer JL, Yee CL, Cooney KA. Risk of second primary tumors in men diagnosed with prostate cancer: a population-based cohort study. Cancer 2014;120:2735-41. doi:10.1002/cncr.28769.
40. Hinnen KA, Schaapveld M, van Vulpen M, et al. Prostate brachytherapy and second primary cancer risk: a competitive risk analysis. J Clin Oncol 2011;29:4510-5. doi:10.1200/JCO.2011.35.0991.
41. Huo D, Hetzel JT, Roy H, Rubin DT. Association of colorectal cancer and prostate cancer and impact of radiation therapy. Cancer Epidemiol Biomarkers Prev 2009;18:1979-85. doi:10.1158/1055-9965. EPI-09-0241.
42. Moon K, Stukenborg GJ, Keim J, Theodorescu D. Cancer incidence after localized therapy for prostate cancer. Cancer 2006;107:991-8. doi:10.1002/cncr.22083.
43. Nieder AM, Porter MP, Soloway MS. Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer: a population based cohort study. J Urol 2008;180:2005-9, discussion 2009-10. doi:10.1016/j.juro.2008.07.038.
44. Rapiti E, Fioretta G, Verkooijen HM, et al. Increased risk of colon cancer after external radiation therapy for prostate cancer. Int J Cancer 2008;123:1141-5. doi:10.1002/ijc.23601.
45. Singh AK, Mashtare TL, McCloskey SA, Seixas-Mikelus SA, Kim HL, May KS. Increasing age and treatment modality are predictors for subsequent diagnosis of bladder cancer following prostate cancer diagnosis. Int J Radiat Oncol Biol Phys 2010;78:1086-94. doi:10.1016/j.ijrobp. 2009.09.055.
46. Van Hemelrijck M, Feller A, Gormo H, et al. Incidence of second malignancies for prostate cancer in the canton of Zurich, 1980-2010. Eur J Cancer 2014;50:S230-31 doi:10.1016/S0959-8049 (14) 50838-6.
47. Overholser L, Garrington T, Greffe B, et al. Managing late and long term effects of childhood cancer treatment. J Gen Intern Med 2010;25:S527.
48. Takam R, Bezak E, Yeoh EE. Risk of second primary cancer following prostate cancer radiotherapy: DVH analysis using the competitive risk model. Phys Med Biol 2009;54:611-25. doi:10.1088/0031-9155/54/3/009.
49. Nguyen PL, Gu X, Lipsitz SR, et al. Cost implications of the rapid adoption of newer technologies for treating prostate cancer. J Clin Oncol 2011;29:1517-24. doi:10.1200/JCO.2010.31.1217.
50. Frezza EE, Wachtel MS, Chiriva-Internati M. Influence of obesity on the risk of developing colon cancer. Gut 2006;55:285-91. doi:10.1136/gut.2005.073163.
51. Engeland A, Tretli S, Bjørge T. Height, body mass index, and prostate cancer: a follow-up of 950000 Norwegian men. Br J Cancer 2003;89:1237-42. doi:10.1038/sj.bjc.6601206.